Urologic Oncology: Seminars and Original Investigations
Volume 28, Issue 2 , Pages 164-169 , March 2010

Prostate stem cell antigen enhancer and uroplakin II promoter based bladder cancer targeted tissue-specific vector

  • Degui Wang, Ph.D.

      Affiliations

    • Institute of Urology, the Second Hospital of Lanzhou University, Lanzhou, China
    • School of Basic Medical Sciences, Lanzhou University, Lanzhou, China
    • ,
  • Zhiping Wang, Ph.D.

      Affiliations

    • Institute of Urology, the Second Hospital of Lanzhou University, Lanzhou, China
    • Corresponding Author InformationCorresponding author. Tel.: +86-931-8942821; fax: +86-931-8942821
    • ,
  • Junqiang Tian, Ph.D.

      Affiliations

    • Institute of Urology, the Second Hospital of Lanzhou University, Lanzhou, China
    • ,
  • Xiangdong He, Ph.D.

      Affiliations

    • Institute of Urology, the Second Hospital of Lanzhou University, Lanzhou, China
    • ,
  • Wasim H. Chowdhury, M.S.

      Affiliations

    • James Buchanan Brady Urology Institute, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA
    • ,
  • Xiangbo Zhang, Ph.D.

      Affiliations

    • Institute of Urology, the Second Hospital of Lanzhou University, Lanzhou, China
    • ,
  • Shigang Li, Ph.D.

      Affiliations

    • Institute of Urology, the Second Hospital of Lanzhou University, Lanzhou, China
    • ,
  • Ronald Rodriguez, M.D., Ph.D.

      Affiliations

    • James Buchanan Brady Urology Institute, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA

Received 4 November 2007 ,Revised 4 February 2008 ,Accepted 5 February 2008.

References 

  1. De-gui W, Ying-xia T, Zhi-ping W. Oncolytic viruses in tumor therapy. J Int Oncol. 2006;33:198–200
  2. Peng XY, Won J, Rutherford T, et al. The use of the L-plastic promoter for adenoviral-mediated, tumor-specific gene expression in ovarian and bladder cancer cell lines. Cancer Res. 2001;61:4405–4413
  3. Li Y, McCadden J, Ferrer F, et al. Prostate-specific expression of the diphtheria toxin A chain (DT-A): Studies of inducibility and specificity of expression of prostate-specific antigen promoter-driven DT-A adenoviral-mediated gene transfer. Cancer Res. 2002;62:2576–2582
  4. Rodriguez JA, Li M, Yao Q, et al. Gene overexpression in pancreatic adenocarcinoma: Diagnostic and therapeutic implications. World J Surg. 2005;29:297–305
  5. Small EJ, Carducci MA, Burke JM, et al. A phase I trial of intravenous CG7870, a replication-selective, prostate-specific antigen-targeted oncolytic adenovirus for the treatment of hormone-refractory, metastatic prostate cancer. Mol Ther. 2006;14:107–117
  6. DeWeese TL, van der Poel H, Li S, et al. A phase I trial of CV706, a replication-competent, PSA selective oncolytic adenovirus, for the treatment of locally recurrent prostate cancer following radiation therapy. Cancer Res. 2001;61:7464–7472
  7. Zhang J, Ramesh N, Chen Y, et al. Identification of human uroplakin II promoter and its use in the construction of CG8840, a urothelium-specific adenovirus variant that eliminates established bladder tumors in combination with docetaxel. Cancer Res. 2002;62:3743–3750
  8. Moll R, Wu X, Lin JH, et al. Uroplakins, specific membrane proteins of urothelial umbrella cells, as histological markers of metastatic transitional cell carcinomas. Am J Pathol. 1995;147:1383–1397
  9. Yuasa T, Yoshiki T, Isono T, et al. Molecular cloning and expression of uroplakins in transitional cell carcinoma. Adv Exp Med Biol. 2003;539:33–46
  10. Zhigang Z, Wenlv S. Prostate stem cell antigen (PSCA) expression in human prostate cancer tissues: Implications for prostate carcinogenesis and progression of prostate cancer. Jpn J Clin Oncol. 2006;36:121
  11. Waeckerle-Men Y, Uetz-von Allmen E, Fopp M, et al. Dendritic cell-based multi-epitope immunotherapy of hormone-refractory prostate carcinoma. Cancer Immunol Immunother. 2006;55:1524–1533
  12. Amara N, Palapattu GS, Schrage M, et al. Prostate stem cell antigen is overexpressed in human transitional cell carcinoma. Cancer Res. 2001;61:4660–4665
  13. Argani P, Rosty C, Reiter RE, et al. Discovery of new markers of cancer through serial analysis of gene expression: prostate stem cell antigen is overexpressed in pancreatic adenocarcinoma. Cancer Res. 2001;61:4320–4324
  14. Jain A, Lam A, Vivanco I, et al. Identification of an androgen-dependent enhancer within the prostate stem cell antigen gene. Mol Endocrinol. 2002;16:2323–2337
  15. Adams JY, Johnson M, Sato M, et al. Visualization of advanced human prostate cancer lesions in living mice by a targeted gene transfer vector and optical imaging. Nat Med. 2002;8:891–897
  16. Zhu H, Zhang ZA, Xu C, et al. Targeting gene expression of the mouse uroplakin II promoter to human bladder cells. Urol Res. 2003;31:17–21
  17. Gu Z, Thomas G, Yamashiro J, et al. Prostate stem cell antigen (PSCA) expression increases with high Gleason score, advanced stage and bone metastasis in prostate cancer. Oncogene. 2000;19:1288–1296
  18. Wente MN, Jain A, Kono E, et al. Prostate stem cell antigen is a putative target for immunotherapy in pancreatic cancer. Pancreas. 2005;31:119–125
  19. Elsamman E, Fukumori T, Kasai T, et al. Prostate stem cell antigen predicts tumor recurrence in superficial transitional cell carcinoma of the urinary bladder. BJU Int. 2006;97:1202–1207

☆ This work was supported by the Natural Science Foundation of China (NSFC 30772177).

PII: S1078-1439(08)00035-5

doi: 10.1016/j.urolonc.2008.02.002

Urologic Oncology: Seminars and Original Investigations
Volume 28, Issue 2 , Pages 164-169 , March 2010

Article Tools

* Image Usage & Resolution